huCD7/huCD20 Mouse
Product Name
huCD7/huCD20 Mouse
Product ID
C002128
Strain Name
C57BL/6Cya-Cd7tm1(hCD7)Ms4a1em1(hMS4A1)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huCD7/huCD20 Mouse (Catalog C002128) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Gene Name
CD7 & MS4A1
Gene Alias
GP40, TP41, Tp40, LEU-9, B1, S7, Bp35, CD20, FMC7, CVID5, LEU-16
NCBI ID
Chromosome
Chr 17 (Human), Chr 11 (Human)
Datasheet
Strain Description
The CD7 gene encodes a transmembrane glycoprotein in the immunoglobulin superfamily (IgSF). As an important co-receptor on the T cell surface, it plays a key regulatory role in T cell activation, proliferation, and signal transduction. CD7 is mainly expressed in T cells and natural killer (NK) cells, from early thymocyte development to the mature T cell stage, and also in some hematopoietic progenitor cells; however, its expression level is low in most normal non-T cell and NK cell tissues [1]. Abnormal expression or dysregulated signaling of CD7 is closely related to multiple diseases. As an important target for immunotherapy, CD7 has become a key molecule for targeting T-cell malignancies due to its high expression in T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and other T-cell malignant tumors [1]. In addition, CD7 is also associated with systemic sclerosis (SSc) and graft-versus-host disease (GvHD) [2-3].
Cluster of differentiation 20 (CD20), also known as MS4A1, is a functional receptor molecule on the surface of B lymphocytes, closely related to B cell activation, signal transduction, and growth regulation. CD20 is expressed at the late stage of B-cell lymphopoiesis and disappears after differentiation into plasma cells. Therefore, CD20 is expressed from pre-B cells to mature B cells, but not in plasma cells [4].
The huCD7/huCD20 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD20 mouse (Catalog No.: C001625). This model can be used for studying the immune mechanisms of CD7/CD20-related malignant tumors, as well as for screening, efficacy evaluation, and safety assessment of CD7/CD20-targeted drugs.
Reference
Freiwan A, Zoine JT, Crawford JC, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684-2696.
Papadimitriou Theodoros Ioannis, Singh Prashant, et al.CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion. Ann Rheum Dis. 2024;83(4):488-498.
Tingting Yang, et al. Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies. Blood. 2025;146(1):1040.
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994 Sep;15(9):450-4.
Strain Strategy
The huCD7/huCD20 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD20 mouse (Catalog No.: C001625).
Figure 1. Gene editing strategy of huCD7 mice. The mouse Cd7 endogenous signal peptide and extracellular domain were replaced with the human CD7 signal peptide and extracellular domain. The expression of mouse Gm11775 would be affected by this KI region.
Figure 2. Gene editing strategy of huCD20(MS4A1) mice. The sequence from the ATG start codon to the TAA stop codon of the endogenous mouse Ms4a1 gene was replaced with the sequence from the ATG start codon to the TAA stop codon of the human MS4A1 gene.
Application Area
Research on the immune mechanisms of CD7/CD20-associated malignancies;
Screening, efficacy evaluation, and safety assessment of CD7/CD20-targeted drugs.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.